Company news: Ipsen, AccentHealth TV

Share this article:

Biotech Ipsen Operations appointed a new nine-person management team that will focus on its rare disease medications Somatuline Depot (lanreotide), for the hormonal growth disorder acromegaly, and Dysport (abobotulinumtoxinA) for cervical dystonia. This is just one of a series of changes—the company recently moved the hub of its US operations from California to the East Coast and announced it was investing $45 million into its R&D facility in Milford, MA. The nine-member management team includes President and General Manager, North America, Sean McKercher. McKercher helped establish the company's foothold in the US while vice president of commercial development. He will report to COO and EVP Christophe Jean.

Waiting room broadcaster AccentHealth TV added eight new condition-specific networks to its nine existing networks, which launched in May 2011. The new networks include arthritis pain, COPD, smoking cessation, gout, low testosterone, MS, osteoporosis and overactive bladder. The company also operates networks with content on allergy, mental health, asthma, diabetes, GERD, rheumatology, heart health, men's health and senior women's health.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.